LEADER 01643nam 2200385 n 450 001 996394326103316 005 20200824121708.0 035 $a(CKB)4940000000122507 035 $a(EEBO)2264213063 035 $a(UnM)ocm99885434e 035 $a(UnM)99885434 035 $a(EXLCZ)994940000000122507 100 $a19960426d1688 uh 101 0 $aeng 135 $aurbn||||a|bb| 200 10$aBy the King, a proclamation of pardon$b[electronic resource] 210 $aLondon $cprinted by Charles Bill, Henry Hills, and Thomas Newcomb, printers to the King's most Excellent Majesty$d1688 215 $a1 sheet ([1] p.) 300 $a"Offers free and absolute pardon to all subjects who have joined the Prince of Orange, and pardon and protection to foreigners who submit themselves within twenty days." -- Steele. 300 $aAt end of text: Given at Our court at Salisbury the 22th day of November, 1688. In the fourth year of Our reign. 300 $aSteele notation: Arms 107 up of li-. 300 $aReproduction of original in the British Library. 330 $aeebo-0018 606 $aPardon$zEngland$vEarly works to 1800 607 $aIreland$xHistory$yWar of 1689-1691$vEarly works to 1800 607 $aGreat Britain$xPolitics and government$y1660-1688$vEarly works to 1800 607 $aGreat Britain$xHistory$yJames II, 1685-1688$vEarly works to 1800 615 0$aPardon 701 $aJames$cKing of England,$f1633-1701.$01001114 801 0$bCu-RivES 801 1$bCu-RivES 906 $aBOOK 912 $a996394326103316 996 $aBy the King, a proclamation of pardon$92305163 997 $aUNISA LEADER 04897nam 2200553Ia 450 001 9910786950903321 005 20230803030444.0 010 $a1-61705-130-6 035 $a(CKB)2670000000387536 035 $a(EBL)1218689 035 $a(OCoLC)851972265 035 $a(SSID)ssj0000916144 035 $a(PQKBManifestationID)12402809 035 $a(PQKBTitleCode)TC0000916144 035 $a(PQKBWorkID)10874728 035 $a(PQKB)10962089 035 $a(MiAaPQ)EBC1218689 035 $a(EXLCZ)992670000000387536 100 $a20130220d2013 uy 0 101 0 $aeng 135 $aur|n|---uuuuu 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aOncology boards flash review$b[electronic resource] /$fFrancis P. Worden, Rami N. Khoriaty, editors ; Binu Malhotra, Brian Parkin, associate editors 210 $aNew York $cDemos Medical Pub.$dc2013 215 $a1 online resource 300 $aIncludes index. 311 $a1-936287-81-1 327 $aCover; Title; Copyright; Contents; Contributors; Preface; Part I: Hematologic Malignancies; Chapter 1: Acute Myeloid Leukemia; Epidemiology; Etiology and Risk Factors; Classification; Signs and Symptoms; Diagnostic Criteria; Indications for Treatment; Prognostic Factors; Treatment; Acute Lymphoblastic Leukemia (ALL); Hairy Cell Leukemia (HCL); Chapter 2: Chronic Lymphocytic Leukemia; Epidemiology; Etiology and Risk Factors; Staging; Signs and Symptoms; Diagnostic Criteria; Indications for Treatment; Prognostic Factors; Treatment; Special Considerations 327 $aChapter 3: Chronic Myeloid Leukemia and Myeloproliferative NeoplasmsChronic Myelogenous Leukemia (CML); Myeloproliferative Neoplasms (General); Polycythemia Vera (PV); Essential Thrombocythemia (ET); Primary Myelofibrosis (PMF); Chapter 4: Myelodysplastic Syndromes; Epidemiology; Etiology and Risk Factors; Classification; Signs and Symptoms; Diagnostic Criteria; Prognostic Factors; Indications for Treatment; Treatment; Chapter 5: Hodgkin's Lymphoma; Epidemiology; Etiology and Risk Factors; Staging; Signs and Symptoms; Diagnostic Criteria; Indications for Treatment; Prognostic Factors 327 $aTreatmentSpecial Considerations; Chapter 6: Non-Hodgkin's Lymphoma-Low Grade; Epidemiology; Etiology and Risk Factors; Staging; Signs and Symptoms; Follicular Lymphoma; Marginal Zone Lymphoma; Lymphoplasmacytic Lymphoma/Waldenstro?m's Macroglobulinemia; Small Lymphocytic Lymphoma (See Chapter 2); Chapter 7: Non-Hodgkin's Lymphoma-High Grade; Diffuse Large B-Cell Lymphoma (DLBCL); Burkitt's Lymphoma (BL); Mantle Cell Lymphoma (MCL); Lymphomas in HIV/AIDS Patients; Chapter 8: Peripheral T-Cell Lymphomas; Epidemiology; Etiology and Risk Factors; Staging; Signs and Symptoms; Diagnostic Criteria 327 $aIndications for TreatmentPrognostic Factors; Treatment; Special Considerations; Chapter 9: Multiple Myeloma and Plasma Cell Dyscrasias; Epidemiology; Etiology and Risk Factors; Staging; Signs and Symptoms; Diagnostic Criteria; Indications for Treatment; Prognostic Factors; Treatment; Special Considerations; Part II: Aerodigestive Malignancies; Chapter 10: Non-Small Cell Lung Cancer; Epidemiology; Etiology and Risk Factors; Screening; Prevention; Pathology; Signs and Symptoms; Diagnostic Workup; Staging; General Treatment Principles; Treatment by Stage; Chapter 11: Small Cell Lung Cancer 327 $aEpidemiologyEtiology and Risk Factors; Staging; Signs and Symptoms; Diagnosis; Prognostic Factors; Treatment; Chapter 12: Malignant Pleural Mesothelioma; Epidemiology; Etiology and Risk Factors; Staging and Histological Classification; Signs and Symptoms; Diagnosis; Prognostic Factors; Treatment; Special Considerations; Chapter 13: Thymoma and Thymic Carcinoma; Epidemiology; Etiology and Risk Factors; Staging and Histological Classification; Signs and Symptoms; Diagnosis; Prognostic and Risk Factors; Treatment; Special Considerations 327 $aChapter 14: Head and Neck Cancers and Salivary Gland Tumors 330 $aCoverage extends across the range of major hematologic malignancies and solid tumors, as well as reviews of pharmacology, biostatistics, genetics and tumor biology, and survivorship and palliative care. Each topic is consistently presented with the key points summarized in bullet point form for easy recall. Question-based headings enable the reader to systematically review and assess his knowledge. 606 $aOncology$xExaminations$vStudy guides 606 $aCancer$xExaminations$vStudy guides 615 0$aOncology$xExaminations 615 0$aCancer$xExaminations 676 $a616.994 701 $aWorden$b Francis P$01044247 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910786950903321 996 $aOncology boards flash review$93755591 997 $aUNINA